Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe
5.10.2021 10:00:00 EEST | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX) today announced its broad European launch of the Novodiag® system, a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. The launch follows Hologic’s acquisition of Mobidiag Oy in June 2021 and will bring the benefits of the Novodiag system to a broader range of customers in Europe.
The Novodiag system combines real-time PCR and microarray capabilities. This enables multiple pathogens to be identified in a single sample, providing a simple and fast way to pinpoint patients most at risk with targeted and syndromic on-demand testing. Its CE-IVD test menu includes highly multiplexed on-demand assays detecting gastrointestinal infections and antibiotic resistance, as well as a targeted assay for the detection of SARS-CoV-2. A strong pipeline is also in development.
“Our acquisition of Mobidiag was aimed at strengthening our international diagnostics business. With the Hologic launch of the Novodiag system, we are delivering against this goal,” said Jan Verstreken, Group President, International at Hologic. “The addition of the Novodiag system to our diagnostic molecular scalable solutions portfolio will offer more customers in Europe a wider choice of solutions that meet their needs, from single patient rapid testing to population-level screening.”
Hologic’s current diagnostic offering is anchored by the Panther® System, a best-in-class, fully automated, sample-to-result platform designed to be used across laboratories of varying throughputs. The Novodiag system is a high multiplex technology that is precision-engineered for simplicity, accuracy and affordability across a broad and growing menu of high- and low-plex assays. It complements the Panther System, along with Panther Scalable Solutions, and expands Hologic’s offering, allowing the Company to meet customers’ growing diagnostic testing needs from small to the largest laboratories.
Tuomas Tenkanen, CEO, Mobidiag, a Hologic company said, “Mobidiag is already realizing the benefits of being part of the Hologic family, and today’s launch will allow Novodiag to reach a far broader customer market faster, delivering the benefits of an on-demand system that offers ease of use, high multiplex capability and a rapid turnaround time.”
For more information visit https://www.hologic.com/hologic-products/novodiag-system.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, Mobidiag, Novodiag, Panther and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about launching the Novodiag system and related assays. There can be no assurance that these products will achieve the benefits described herein, that they will be commercially successful or achieve any expected level of sales, or that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
SOURCE: Hologic, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005411/en/
Contact information
Hologic
Investor Contact:
Michael Watts
+1 858.410.8588
michael.watts@hologic.com
Media Contact:
Jane Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 08:00:00 EET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, Relfydess and the Restylane range.1-9 This comprehensive scientific presence reflects Galderma’s holistic, trend‑led approach to innovation, and its commitment to addressing emerging needs such as menopause‑related skin changes, the growing interest in regenerative treatments, and the rising demand for body injectables. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316497387/en/ “Patients’ needs are changing faster than ever, whether that’s navigating the skin changes associated with menopause, seeking regenerative benefits, or looking for aesthetic harmony beyond the face. The data
Fujirebio Announces CE Marking of the Fully Automated Lumipulse ® G Nfl Blood Assay17.3.2026 08:00:00 EET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 03:00:00 EET | Press release
Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cross-border collaboration are existential priorities, Miro provides the link between human creativity and AI capa
IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 23:24:00 EET | Press release
Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink As enterprises and public institutions worldwide move from quantum exploration to long-term deployment, the challenge has evolved beyond simply accessing quantum hardware. The focus is now on reliably operating quantum computers, seamlessly integrating them into existing compute infrastructure, and scaling them toward fault tolerance. The announced project directly addresses these needs by focusing on full-system integration f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom